The Jackson Laboratory (JAX) completed its acquisition of the New York Stem Cell Foundation (NYSCF) and launched a unified organization in New York City, integrating JAX’s genetics and mouse‑model expertise with NYSCF’s human stem‑cell automation. JAX leaders highlighted translational ambitions, citing a case where a custom gene therapy reached a patient within seven months as a proof of concept. The merger combines JAX’s global infrastructure with NYSCF’s robotic stem‑cell array to scale reproducible human stem‑cell research. Officials, including former NIH director Francis Collins, attended the ribbon‑tying event and emphasized the potential to accelerate genomic solutions and translational pipelines for rare diseases and regenerative medicine.